Prince and colleagues [9], demonstrated that a minor population of CD44+ HNSCC-cells possess CSC characteristics, which could give rise to new tumors in vivo (≈5,000 cells injected). The gene discussed is CD44; the disease is head and neck squamous cell carcinoma.